@article { author = {}, title = {Novel target of the 4-piperidone thiazole derivative for platelet inhibitions by using inducers collagen and ADP}, journal = {Health Biotechnology and Biopharma (HBB)}, volume = {5}, number = {3}, pages = {1-16}, year = {2021}, publisher = {Health Biotechnology and Biopharma}, issn = {2538-4414}, eissn = {2538-4414}, doi = {10.22034/HBB.2021.19}, abstract = {Platelets are thought to aid in hemostasis, thrombosis, inflammation, wound healing, and immunity. R4 is a novel thiazole derivative that may decrease angina and ischemia. An aggregometer evaluated R4 impact on PRP. Spectrophotometric method measured anti-lipoxygenase activity of R4. In its absence, the platelet aggregation in PRP showed 88 % and 75 % with collagen and ADP, respectively, while R4 inhibited 100 % collagen-induced platelet aggregation at 1.1875 μM and ADP-induced platelet aggregation up to 100 % at 0.9375 μM. Collagen and ADP induced R4 antiplatelet IC50 values were 0.55 ± 0.12 μM, and 0.26 ± 0.20 μM, respectively. R4 inhibited lipoxygenase significantly with an IC50 of 26.65 ± 0.16 μM. The novel compound, R4, may also assist platelet-associated thromboembolic disorders.}, keywords = {Aggregation,Platelets,collagen,ADP,thiazole derivatives,4-piperidone,THR}, url = {https://www.healthbiotechpharm.org/article_141537.html}, eprint = {https://www.healthbiotechpharm.org/article_141537_4fc1498a85af7921e568e7678126596c.pdf} } @article { author = {}, title = {Evaluating the level of knowledge of people referring to the comprehensive health services center about crimean congo hemorrhagic fever}, journal = {Health Biotechnology and Biopharma (HBB)}, volume = {5}, number = {3}, pages = {17-22}, year = {2021}, publisher = {Health Biotechnology and Biopharma}, issn = {2538-4414}, eissn = {2538-4414}, doi = {10.22034/HBB.2021.20}, abstract = {Since crimean congo hemorrhagic fever can be prevented with simple methods, people awareness and prevention of this disease is important. In this study, the level of knowledge about this disease and the factors affecting the knowledge of people were investigated in Yazd. In this study, 220 people referred to the comprehensive health services center in Yazd were included in the study and a questionnaire of knowledge of people level was completed. Then the obtained information was entered into statistical software. Only 30 % of people were aware of crimean congo hemorrhagic fever.}, keywords = {Crimean Congo hemorrhagic fever,knowledge of people,Yazd}, url = {https://www.healthbiotechpharm.org/article_141538.html}, eprint = {https://www.healthbiotechpharm.org/article_141538_8435efa77383107fd866305e8e2ce6a2.pdf} } @article { author = {}, title = {Cardioprotective effects of extract of Sclerocarya birrea stem bark on doxorubicin induced cardiotoxicity in rats}, journal = {Health Biotechnology and Biopharma (HBB)}, volume = {5}, number = {3}, pages = {23-43}, year = {2021}, publisher = {Health Biotechnology and Biopharma}, issn = {2538-4414}, eissn = {2538-4414}, doi = {10.22034/HBB.2021.21}, abstract = {This study aimed to investigate the protective effect of methanol extract of Sclerocarya birrea (S. birrea) stem bark on Doxorubicin (DOX) induced cardiotoxicity in rats. Tissue Malondialdehyde (MDA) level was increased in DOX treated group while activities of antioxidant maker enzymes; Catalase (CAT), Superoxide Dismutase (SOD) were significantly decreased. Cardiotoxicity was further confirmed by significant increase in the serum levels of cardiac markers; troponin, creatine kinase, aspartate transaminase and myoglobin in DOX treated group. Histological examinations show that S. birrea at 600 mg/kg have improved the heart structural abnormalities induced by DOX. This showed that the S. birrea stem bark extract had potential to prevent oxidative damage induced by DOX in the heart and could serve as novel adjuvant antioxidant therapy with chemotherapeutic agents.}, keywords = {doxorubicin,Sclerocarya birrea,Myocardial Infarction,adjuvant,chemotherapeutic}, url = {https://www.healthbiotechpharm.org/article_141539.html}, eprint = {https://www.healthbiotechpharm.org/article_141539_e44b5d1385fe7f5d345bcec737fb5884.pdf} } @article { author = {}, title = {Construction of a chimeric FliC including epitopes of OmpA and OmpK36 as a multi-epitope vaccine against Klebsiella pneumonia}, journal = {Health Biotechnology and Biopharma (HBB)}, volume = {5}, number = {3}, pages = {44-60}, year = {2021}, publisher = {Health Biotechnology and Biopharma}, issn = {2538-4414}, eissn = {2538-4414}, doi = {10.22034/HBB.2021.22}, abstract = {OmpA and OmpK36 from K. pneumoniae as the antigens and FliC from Salmonella typhimurium as the adjuvant were applied to construct a multi-epitope vaccine. B-cell, T-cell, and IL-17-epitopes were identified and a construct was modeled. Molecular docking was performed to assess the interaction between chimeric FliC and TLR-5. Downstream analysis including antigenicity, allergenicity, IFN-γ and IL-4 epitopes prediction was done. This construction covers both B-cell and T-cell epitopes as well as IFN-γ and IL-4 epitopes, but no IL-17 epitope was detected. We used two other known epitopes (IEDB epitope ID 43662 and epitope ID 57417) that induce the IL-17 release. According to the result, the multi-epitope protein is probable antigen and not an allergen. This construction was stable, hydrophilic, and has no transmembrane helixes. The computer-aided analysis imply that this protein is an acceptable candidate for immunization against K. pneumoniae.}, keywords = {Klebsiella pneumoniae,multi-epitope vaccine,Chimeric Protein,In silico analysis}, url = {https://www.healthbiotechpharm.org/article_141541.html}, eprint = {https://www.healthbiotechpharm.org/article_141541_2aab84295b42c41c3566d34a9caa8bf4.pdf} } @article { author = {}, title = {The most common symptoms of COVID-19 patients in Yazd}, journal = {Health Biotechnology and Biopharma (HBB)}, volume = {5}, number = {3}, pages = {61-71}, year = {2021}, publisher = {Health Biotechnology and Biopharma}, issn = {2538-4414}, eissn = {2538-4414}, doi = {10.22034/HBB.2021.23}, abstract = {The aim of this study was to investigate the most common symptoms of COVID-19 patients in Yazd. This study was done during 2020-2021. All patients with positive PCR test were entered to this study. Finally, data was analyzed by SPSS software. The most common symptoms of COVID-19 patients were shortness of breath, fever and cough. There was a significant relationship between diabetes, lethargy, myalgia, chills, fever and loss of taste. Several symptoms including weakness, lethargy, dry cough, decreased appetite, were significantly more in the autumn season. According to the findings, the symptoms could have different prevalence in patients with underlying disease.}, keywords = {COVID-19,manifestations,Symptoms,Yazd}, url = {https://www.healthbiotechpharm.org/article_141542.html}, eprint = {https://www.healthbiotechpharm.org/article_141542_3b191c092af026f9bef37afc139b571b.pdf} } @article { author = {}, title = {Strategies in design of antibodies for cancer treatment}, journal = {Health Biotechnology and Biopharma (HBB)}, volume = {5}, number = {3}, pages = {72-96}, year = {2021}, publisher = {Health Biotechnology and Biopharma}, issn = {2538-4414}, eissn = {2538-4414}, doi = {10.22034/HBB.2021.24}, abstract = {Structural bioinformatics and computational methodologies facilitate antibodies design. The rational design is used to achieve a new function or adopt a new structure. Computer algorithms can systematically search amino acid sequences and select the best one. One of the important points of protein therapeutics is utilizing as drug. The present study reviewed recent studies about antibody design, antibody structure modeling, antibody prediction, and stability, pharmacokinetics and recent algorithms used in antibody design. By advanced technology with computational technologies development of therapeutics antibodies is possible. In early stages, several methods of predicting protein structure and de novo protein design were presented.}, keywords = {Antibody design,Nano-carriers,pharmacokinetics property,Docking,algorithms}, url = {https://www.healthbiotechpharm.org/article_141543.html}, eprint = {https://www.healthbiotechpharm.org/article_141543_b1a494c86cebf5ac09cda68f0b2c3daa.pdf} }